All In Biotech

Drug Trial Radar · NCT07331389

A Drug-Drug Interaction Study of HDM1002 and Metformin, Empagliflozin, Midazolam, Valsartan, and Warfarin

A Phase I, Single-center, Open-Label, Single-Arm, Fixed-Sequence Study to Evaluate the Drug-Drug Interaction of HDM1002 and Metformin, Empagliflozin, Midazolam, Valsartan, and Warfarin in Overweight/Obese Adult Chinese Subjects

Last checked: Nov 19, 2026Latest source record: Jan 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

111

Planned (sponsor's estimate)

Start

Sep 24, 2025

Primary completion

Jan 12, 2026

Study completion Jun 13, 2026

Sponsor

Sponsor type
Industry
First posted
Jan 9, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to characterize the drug-drug intereaction of HDM1002 and metformin, empagliflozin, midazolam, valsartan, and warfarin in overweight/obese adult subjects. The safety and tolerability of HDM1002 with metformin, empagliflozin, midazolam, valsartan, and warfarin when given separately or together will also be evaluated

Conditions

  • Overweight Subject
  • Healthy Subjects

Interventions

  • MetforminDrug

    Administered orally

  • EmpagliflozinDrug

    Single dose; Administered orally

  • MidazolamDrug

    Single dose; Administered orally

  • ValsartanDrug

    Single dose; Administered orally

  • WarfarinDrug

    Single dose; Administered orally

  • HDM1002Drug

    Administered orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. AUC[0-∞]Time frame: through study completion, an average of 11 weeks
  2. CmaxTime frame: through study completion, an average of 11 weeks
  3. AUC[0-t]Time frame: through study completion, an average of 11 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Second Affiliated Hospital of Anhui Medical University

    Hefei, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.